PARTI Company Overview We are a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines. Our approved product CARDAMYST TM (etripamil) nasal spray is available in the United States and is the first and only FDA approved self-administered treatment for use by patients anywhere, anytime an attack of PSVT occurs. We continue to seek, either directly or through collaboration with our partners, marketing approval from regulatory agencies respo...
Q2 FY2026 — expected 2026-08-09
| Type | Subject | Detail | Quarter |
|---|---|---|---|
| topic_mention | MIST | discussed_in_filing Cybersecurity | |
| topic_mention | MIST | discussed_in_filing Trusted Computing | |
| topic_mention | MIST | discussed_in_filing Blockchain & Crypto | |
| topic_mention | MIST | discussed_in_filing Supply Chain | |
| topic_mention | MIST | discussed_in_filing Regulation | |
| topic_mention | MIST | discussed_in_filing Healthcare & Bio | |
| topic_mention | MIST | discussed_in_filing Sovereign & Government | |
| topic_mention | MIST | discussed_in_filing Cybersecurity | |
| topic_mention | MIST | discussed_in_filing Trusted Computing | |
| topic_mention | MIST | discussed_in_filing Blockchain & Crypto | |
| topic_mention | MIST | discussed_in_filing Supply Chain | |
| topic_mention | MIST | discussed_in_filing Regulation | |
| topic_mention | MIST | discussed_in_filing Healthcare & Bio | |
| topic_mention | MIST | discussed_in_filing Sovereign & Government | |
| topic_mention | MIST | discussed_in_filing Cybersecurity | |
| topic_mention | MIST | discussed_in_filing Trusted Computing | |
| topic_mention | MIST | discussed_in_filing Blockchain & Crypto | |
| topic_mention | MIST | discussed_in_filing Supply Chain | |
| topic_mention | MIST | discussed_in_filing Regulation | |
| topic_mention | MIST | discussed_in_filing Healthcare & Bio |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-20 | 2025-12-31 | 0001104659-26-032415 | EDGAR | 83K words |
| 2025-03-13 | 2024-12-31 | 0001558370-25-002849 | EDGAR | — |
| 2024-03-21 | 2023-12-31 | 0001558370-24-003666 | EDGAR | — |
| 2023-03-29 | 2022-12-31 | 0001558370-23-004871 | EDGAR | — |
| 2022-03-24 | 2021-12-31 | 0001558370-22-004205 | EDGAR | — |
| 2021-03-29 | 2020-12-31 | 0001558370-21-003631 | EDGAR | — |
| 2020-03-06 | 2019-12-31 | 0001558370-20-002106 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-12 | 2025-09-30 | 0001104659-25-109689 | EDGAR | 28K words |
| 2025-08-12 | 2025-06-30 | 0001558370-25-011141 | EDGAR | — |
| 2025-05-14 | 2025-03-31 | 0001558370-25-007648 | EDGAR | — |
| 2024-11-12 | 2024-09-30 | 0001558370-24-015147 | EDGAR | — |
| 2024-08-08 | 2024-06-30 | 0001558370-24-011603 | EDGAR | — |
| 2024-05-13 | 2024-03-31 | 0001558370-24-007860 | EDGAR | — |
| 2023-11-13 | 2023-09-30 | 0001558370-23-018665 | EDGAR | — |
| 2023-08-10 | 2023-06-30 | 0001558370-23-014399 | EDGAR | — |
| 2023-05-11 | 2023-03-31 | 0001558370-23-009254 | EDGAR | — |
| 2022-11-10 | 2022-09-30 | 0001558370-22-017283 | EDGAR | — |
| 2022-08-10 | 2022-06-30 | 0001558370-22-013074 | EDGAR | — |
| 2022-05-12 | 2022-03-31 | 0001558370-22-008418 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-20 | 0001104659-26-032427 | EDGAR | 4K words |
| 2026-01-26 | 0001104659-26-006483 | EDGAR | — |
| 2026-01-13 | 0001104659-26-003038 | EDGAR | — |
| 2026-01-06 | 0001104659-26-001099 | EDGAR | — |
| 2025-12-15 | 0001104659-25-120904 | EDGAR | — |
| 2025-11-12 | 0001104659-25-109744 | EDGAR | — |
| 2025-08-12 | 0001104659-25-076468 | EDGAR | — |
| 2025-07-14 | 0001104659-25-067579 | EDGAR | — |
| 2025-07-11 | 0001104659-25-067108 | EDGAR | — |
| 2025-06-16 | 0001104659-25-059671 | EDGAR | — |
124 total filings indexed. 95 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001408443 |
| Ticker | MIST |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | A8 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report